BioSyent Releases First Six Months 2015 Results-Six Month Sales Up 25%; Pharma Sales Up 25%; EBITDA Up 31%; Net Income Up 30%; Return on Equity 40%
TORONTO, ONTARIO--( Aug. 12, 2015) - BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) released today a summary of its Second Quarter (Q2 2015) and first half financial results for the three and six months ending June 30, 2015. Key highlights include:
- First six months (H1 2015) Sales of $6,900,098 increased by 25% versus H1 2014
-
H1 2015 Pharma sales of $6,565,300 increased by 25% versus H1 2014
- Published: 12 August 2015
- Written by Editor